Anti-amyloid-β single-chain antibody brain delivery via aav reduces amyloid load but may increase cerebral hemorrhages in an alzheimer's disease mouse model

Journal of Alzheimer's Disease

Volumn 27, Issue 1, 2011, Pages 23-28

  Kou, Jinghong ^a   Kim, Hongduck ^b   Pattanayak, Abhinandan ^a   Song, Min ^a,c   Lim, Jeong Eun ^a   Taguchi, Hiroaki ^d   Paul, Sudhir ^d   Cirrito, John R ^e   Ponnazhagan, Selvarangan ^f   Fukuchi, Ken Ichiro ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF TEXAS   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f University of Alabama at Birmingham   (United States)

Author keywords

Adeno associated virus; Alzheimer's disease; amyloid; cerebral hemorrhage; immunotherapy; single chain antibodies

Indexed keywords

AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42];

ADENO ASSOCIATED VIRUS; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BRAIN HEMORRHAGE; CELL ACTIVATION; CEREBROSPINAL FLUID; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; HIPPOCAMPUS; IMMUNOREACTIVITY; MICROGLIA; MOUSE; NEOCORTEX; NONHUMAN; PARENCHYMA; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SEROTYPE; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

EID: 80155190179     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-110230     Document Type: Article

References (49)

1. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356. (Pubitemid 34790756)
2. Schenk D, Barbour R, DunnW, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173-177. (Pubitemid 29327547)
3. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9, 448-452. (Pubitemid 36460079)
4. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61, 6-54.
5. Weiner HL, Selkoe DJ (2002) Inflammation and therapeutic vaccination in CNS diseases. Nature 420, 879-884. (Pubitemid 36019642)
6. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64, 1553-1562. (Pubitemid 40617691)
7. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6, 916-919. (Pubitemid 30644751)
8. Bacskai BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D, Hyman BT (2002) Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci 22, 7873-7878. (Pubitemid 35379092)
9. Das P, Howard V, Loosbrock N, Dickson D, Murphy MP, Golde TE (2003) Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/-knock-out mice. J Neurosci 23, 8532-8538. (Pubitemid 37158753)
10. Ferrer I, Boada RM, Sanchez Guerra ML, Rey MJ, Costa-Jussa F (2004) Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 14, 11-20. (Pubitemid 38200585)
11. Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, Wollmer MA, Umbricht D, de Quervain DJ, Hofmann M, Maddalena A, Papassotiropoulos A, Nitsch RM (2003) Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38, 547-554. (Pubitemid 36645030)
12. Grundman M, Black R (2008) Clinical trials of bapineuzumab, a beta-amyloid-targeted immunotherapy in patients with mild to moderate Alzheimer's disease. Alzheimers Dement 4, T166.
13. Fukuchi KI, Accavitti-Loper M, Kim HD, Tahara K, Cao Y, Lewis TL, Caughey RC, Kim H, Lalonde R (2006) Amelioration of amyloid load by anti-A[beta] single-chain antibody in Alzheimer mouse model. Biochem Biophys Res Commun 344, 79-86.
14. Fukuchi KI, Tahara K, Kim HD, Maxwell JA, Lewis TL, Accavitti-Loper M, Kim H, Ponnazhagan S, LalondeR(2006) Anti-Aß single chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease. Neurobiol Dis 23, 502-511. (Pubitemid 44234087)
15. Grimm D, Kay MA, Kleinschmidt JA (2003) Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol Ther 7, 839-850. (Pubitemid 36790261)
16. Zolotukhin S, Potter M, Zolotukhin I, Sakai Y, Loiler S, Fraites TJ, Jr, Chiodo VA, Phillipsberg T, Muzyczka N, HauswirthWW, Flotte TR, Byrne BJ, Snyder RO (2002) Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28, 158-167. (Pubitemid 35341079)
17. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, Younkin SG, Borchelt DR (2004) Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 13, 159-170. (Pubitemid 38111354)
18. DeMattos RB, Bales KR, Parsadanian M, O'Dell MA, Foss EM, Paul SM, Holtzman DM (2002) Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease. J Neurochem 81, 229-236. (Pubitemid 34809348)
19. Jin JJ, Kim HD, Maxwell JA, Li L, Fukuchi KI (2008) Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease. J Neuroinflammation 5, 23.
20. Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews PM, JuckerM(2002) Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 298, 1379. (Pubitemid 35346131)
21. Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, Piroozi KS, Jordan WH, Brown DD, Hoffman WP, Holtzman DM, Bales KR, Gitter BD, May PC, Paul SM, DeMattos RB (2005) Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci 25, 629-636.
22. Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D (2004) Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 1, 24.
23. Passini MA,Watson DJ,Vite CH, Landsburg DJ, Feigenbaum AL,Wolfe JH (2003) Intraventricular brain injection of adenoassociated virus type 1 (AAV1) in neonatal mice results in complementary patterns of neuronal transduction to AAV2 and total long-term correction of storage lesions in the brains of beta-glucuronidase-deficient mice. J Virol 77, 7034-7040. (Pubitemid 36666896)
24. Levites Y, Jansen K, Smithson LA, Dakin R, Holloway VM, Das P, Golde TE (2006) Intracranial adeno-associated virusmediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice. J Neurosci 26, 11923-11928. (Pubitemid 44772103)
25. Chakrabarty P, Ceballos-Diaz C, Beccard A, Janus C, Dickson D, Golde TE, Das P (2010) IFN-gamma promotes complement expression and attenuates amyloid plaque deposition in amyloid beta precursor protein transgenic mice. J Immunol 184, 5333-5343.
26. Kornum BR, Stott SR, Mattsson B,Wisman L, Ettrup A, Hermening S, Knudsen GM, Kirik D (2010) Adeno-associated viral vector serotypes 1 and 5 targeted to the neonatal rat and pig striatum induce widespread transgene expression in the forebrain. Exp Neurol 222, 70-85.
27. Markakis EA, Vives KP, Bober J, Leichtle S, Leranth C, Beecham J, Elsworth JD, Roth RH, Samulski RJ, Redmond DE, Jr (2010) Comparative transduction efficiency of AAV vector serotypes 1-6 in the substantia nigra and striatum of the primate brain. Mol Ther 18, 588-593.
28. Taymans JM, Vandenberghe LH, Haute CV, Thiry I, Deroose CM, Mortelmans L, Wilson JM, Debyser Z, Baekelandt V (2007) Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. Hum Gene Ther 18, 195-206. (Pubitemid 46626459)
29. BanksWA, Terrell B, Farr SA, Robinson SM, Nonaka N, Morley JE (2002) Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease. Peptides 23, 2223-2226. (Pubitemid 36092057)
30. Levites Y, Das P, Price RW, Rochette MJ, Kostura LA, McGowan EM, MurphyMP, Golde TE (2006) Anti-Abeta42-and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J Clin Invest 116, 193-201. (Pubitemid 43121804)
31. Wang YJ, Pollard A, Zhong JH, Dong XY, Wu XB, Zhou HD, Zhou XF (2009) Intramuscular delivery of a single chain antibody gene reduces brain Abeta burden in a mouse model of Alzheimer's disease. Neurobiol Aging 30, 364-376.
32. Sudol KL, Mastrangelo MA, NarrowWC, Frazer ME, Levites YR, Golde TE, Federoff HJ, Bowers WJ (2009) Generating differentially targeted amyloid-beta specific intrabodies as a passive vaccination strategy for Alzheimer's disease. Mol Ther 17, 2031-2040.
33. Ryan DA, Mastrangelo MA, Narrow WC, Sullivan MA, Federoff HJ, Bowers WJ (2010) Abeta-directed single-chain antibody delivery via a serotype-1 AAV vector improves learning behavior and pathology in Alzheimer's disease mice. Mol Ther 18, 1471-1481.
34. Howard DB, Powers K,Wang Y, Harvey BK (2008) Tropism and toxicity of adeno-associated viral vector serotypes 1, 2, 5, 6, 7, 8, and 9 in rat neurons and glia in vitro. Virology 372, 24-34. (Pubitemid 351215455)
35. Royo NC, Vandenberghe LH, Ma JY, Hauspurg A, Yu L, Maronski M, Johnston J, Dichter MA, Wilson JM, Watson DJ (2008) Specific AAV serotypes stably transduce primary hippocampal and cortical cultures with high efficiency and low toxicity. Brain Res 1190, 15-22.
36. Li SF, Wang RZ, Meng QH, Li GL, Hu GJ, Dou WC, Li ZJ, Zhang ZX (2006) Intra-ventricular infusion of rAAV1-EGFP resulted in transduction in multiple regions of adult rat brain: a comparative study with rAAV2 and rAAV5 vectors. Brain Res 1122, 1-9.
37. Blits B, Derks S, Twisk J, Ehlert E, Prins J, Verhaagen J (2010) Adeno-associated viral vector (AAV)-mediated gene transfer in the red nucleus of the adult rat brain: comparative analysis of the transduction properties of seven AAV serotypes and lentiviral vectors. Neurosci Methods 185, 257-263.
38. Reimsnider S, Manfredsson FP, Muzyczka N, Mandel RJ (2007) Time course of transgene expression after intrastriatal pseudotyped rAAV2/1, rAAV2/2, rAAV2/5, and rAAV2/8 transduction in the rat. Mol Ther 15, 1504-1511. (Pubitemid 47103062)
39. Tahara K, Kim HD, Jin JJ, Maxwell JA, Li L, Fukuchi KI (2006) Role of toll-like receptor signalling in A{beta} uptake and clearance. Brain 129, 3006-3019. (Pubitemid 44684521)
40. Smith EE, Greenberg SM(2009) Beta-amyloid, blood vessels, and brain function. Stroke 40, 2601-2606.
41. Patton RL, Kalback WM, Esh CL, Kokjohn TA, Van Vickle GD, Luehrs DC,Kuo YM, Lopez J, Brune D, Ferrer I, Masliah E, Newel AJ, Beach TG, Castano EM, Roher AE (2006) Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol 169, 1048-1063. (Pubitemid 44411966)
42. Wilcock DM,Munireddy SK, Rosenthal A, Ugen KE, Gordon MN,Morgan D (2004) Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol Dis 15, 11-20. (Pubitemid 38134376)
43. Nicoll JA, Barton E, Boche D, Neal JW, Ferrer I, Thompson P, Vlachouli C, Wilkinson D, Bayer A, Games D, Seubert P, Schenk D, Holmes C (2006) Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol 65, 1040-1048. (Pubitemid 44684661)
44. Nicoll JA, Hawkes C, Holmes C, Weller R, Perry H, Boche D, Teeling J, Carare R (2010) Processes underlying the vascular pathophysiology associated with Aß immunization in Alzheimer's disease. Alzheimers Dement 6, S143.
45. Whitlow M, Bell BA, Feng SL, Filpula D, Hardman KD, Hubert SL, Rollence ML, Wood JF, Schott ME, Milenic DE (1993) An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability. Protein Eng 6, 989-995. (Pubitemid 23347376)
46. Wilcock DM, Colton CA (2009) Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice. CNS Neurol Disord Drug Targets 8, 50-64.
47. Herzig MC, Winkler DT, Burgermeister P, Pfeifer M, Kohler E, Schmidt SD, Danner S, Abramowski D, Sturchler-Pierrat C, Burki K, van Duinen SG, Maat-Schieman ML, Staufenbiel M, Mathews PM, JuckerM(2004) Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat Neurosci 7, 954-960. (Pubitemid 39129504)
48. Fryer JD, Simmons K, Parsadanian M, Bales KR, Paul SM, Sullivan PM, HoltzmanDM(2005) Human apolipoprotein E4 alters the amyloid-beta 40 : 42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J Neurosci 25, 2803-2810. (Pubitemid 40389238)
49. Taguchi H, Planque S, Nishiyama Y, Szabo P, Weksler ME, Friedland RP, Paul S (2008) Catalytic antibodies to amyloid beta peptide in defense against Alzheimer disease.Autoimmun Rev 7, 391-397.